Background and purpose: Two compounds, URB602 and URB754, have been reported in the literature to be selective inhibitors of monoacylglycerol lipase, although a recent study has questioned their ability to prevent 2-arachidonoyl hydrolysis by brain homogenates and cerebellar membranes. In the present study, the ability of these compounds to inhibit monoacylglycerol lipase and fatty acid amide hydrolase has been reinvestigated. Experimental approach: Homogenates and cell lines were incubated with test compounds and, thereafter, with either
Introduction
The primary enzyme involved in the metabolism of the endocannabinoid anandamide (AEA) is fatty acid amide hydrolase (FAAH), and selective inhibitors of this enzyme, such as URB597 (3 0 -carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) have been shown to produce potentially useful effects in models of pain and inflammation (see e.g. Kathuria et al., 2003; Holt et al., 2005; Jayamanne et al., 2006 for studies with this compound). The other main endocannabinoid, 2-arachidonoylglycerol (2-AG) is also metabolized by FAAH (Goparaju et al., 1998) , and microinjection of an FAAH inhibitor into the periaqueductal grey increases 2-AG levels in that region (Maione et al., 2006) . However, the enzyme monoacylglycerol lipase (MAGL), which is capable of hydrolyzing both 2-AG and its oleoyl homologue 2-oleoylglycerol (2-OG) (Tornqvist and Belfrage, 1976; Dinh et al., 2002) , may be a more important metabolic enzyme in the brain for this endocannabinoid (Dinh et al., 2002) . This enzyme is not inhibited by URB597 (Makara et al., 2005) , but is sensitive to the non-selective serine hydrolase inhibitor methyl arachidonoyl fluorophosphonate (MAFP) (Dinh et al., 2002;  (Makara et al., 2005) . In contrast, Saario et al. (2006) found that a concentration of 1 mM of URB602 did not affect the hydrolysis of 2-AG by either rat brain homogenates or rat cerebellar membrane fractions. An even larger difference was seen with respect to another compound, URB754 (6-methyl-2-[(4-methylphenyl) amino]-4H-3,1-benzoxazin-4-one), which was identified when a library of compounds was screened towards recombinant MAGL and was demonstrated to inhibit this enzyme with an IC 50 value of 200 nM (Makara et al., 2005) . Commercially available URB754, however, did not inhibit 2-AG metabolism in the brain homogenates and cerebella membranes at a concentration of 100 mM (Saario et al., 2006) . In order to shed further light upon the pharmacology of these compounds, we have investigated their ability to prevent 2-OG hydrolysis, using membrane and cytosolic sources of the enzyme, recombinant human MAGL and intact cells. Also, the selectivity of these compounds for 2-OG compared to AEA hydrolysis has been determined.
Methods
Cell-free preparations for MAGL and FAAH assays Cerebella from adult male Wistar rats were used. These were thawed and homogenized at 41C in sodium phosphate buffer (50 mM, pH 8) containing 0.32 M sucrose. Homogenates were centrifuged at 100 000 g for 60 min at 41C, and supernatants ('cytosol fractions') were collected. The pellets were resuspended in sodium phosphate buffer (50 mM, pH 8) ('membrane fractions'). The fractions were stored frozen in aliquots at À701C until used for assay of either rat MAGL or FAAH, as appropriate. Data for human MAGL were obtained using recombinant enzyme purified and expressed in Escherichia Coli by co-author Labar, the protocol of which will be published elsewhere. Protein concentrations of the fractions were determined by using the method described by Harrington (1990) , with bovine serum albumin (BSA) as standard. Ethical permission for the animals was obtained from the local animal ethical committee. ).
Preparation of cell cultures

Assay of MAGL and FAAH
For cell-free preparations, MAGL and FAAH were assayed as described previously (see Vandevoorde et al., 2005) , although for the experiments run in Sweden a different extraction protocol (Boldrup et al., 2004) was used for the three highest concentrations of URB602 and for FAAH; data shown as an inset to Figure 1a . For intact cells, a modification of the assay described by Jonsson et al. (2001) was used. Cells (2.5 Â 10 5 per well) were cultured overnight in 24-well culture plates. The cells were then washed once with 500 ml of KrebsHenseleit-Bicarbonate buffer (120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl 2 , 10 mM 4-(2-hydroxyethyl)-1-piperazineethylsulphonic acid (HEPES), 0.12 mM KH 2 PO 4 , 0.12 mM MgSO 4 in milliQ deionized water, pH 7.4) containing 1% w v À1 BSA. Thereafter Krebs-Henseleit-Bicarbonate buffer was added followed by test compound, and the samples were incubated for 10-60 min at 371C. Substrate (0.25 mM final concentration, in buffer containing fatty acid-free BSA at a final assay concentration 0.1% w v
À1
) was added to give an assay volume of 400 ml. The samples were incubated for the times shown in the figure legend, then the plates were placed upon ice. Methanol (400 ml) was added and the cells were collected by scraping the wells. Aliquots (400 ml) were transferred to glass tubes, chloroform (200 ml) was added, and the assays completed as described for the cell-free preparations (Vandevoorde et al., 2005) . Results are expressed as percentage of controls treated with the same concentration of vehicle.
It should be pointed out that the assay used, although a 'standard' method, separates the product of enzyme action upon 2-OG on the basis of its partition into the methanol/ water phase vs the chloroform phase but is not necessarily specific for MAGL. Treatment of rat brain cytosolic fractions with an antibody to MAGL reduces, but does not completely block their ability to hydrolyze 2-OG (Dinh et al., 2004) , suggesting that additional enzymes may be operative. 2-OG (and 2-AG) are substrates for a family of monoacylglycerol kinases, which produce lyso-phosphatidic acids, although these products would be expected to be retained in the chloroform phase (see e.g. Simpson et al., 1991; Waggoner et al., 2004) . However, other esterases may be involved. In this respect, the esterase domain of human neuropathy target esterase can also hydrolyze 2-OG (and 2-AG), and can be inhibited by the serine hydrolase inhibitor MAFP (van Tienhoven et al., 2002) . Hence, we have referred to this process throughout as '2-OG hydrolysis' rather than as MAGL activity, except when the recombinant enzyme has been used.
RNA extraction and polymerase chain reactions RNA extraction and polymerase chain reactions (PCR) were undertaken by standard methods, using RNAqueous-4PCR kit for RNA isolation, a first strand cDNA synthesis kit using oligo(dT) 15 primers for reverse transcription (RT) into single-stranded cDNA and a PC-960G Gradient Thermal Cycler (Corbett Research, Mortlake, Australia) for PCR. The sequences of primers used were: rat MAGL sense 0 . The expression of the target genes was compared at the logarithmic phase of the PCR reaction. No amplification was detected in samples where the RT reaction had been omitted. The PCR products for the C6 and RBL2H3 cells were purified using a QIAquick purification kit using the protocol supplied by the manufacturer, and the identities were confirmed using a Thermo-Sequenase-TM-II DYEnamic ET terminator cycle sequencing kit with sequences analysed on an ABI 377 XL DNA Sequencer (Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Curve fitting and statistical comparisons were undertaken using the statistical package in the GraphPad Prism computer programme (GraphPad Software Inc., San Diego, CA, USA). IC 50 values were determined using the sigmoidal doseresponse curve (variable slope) analysis provided by the programme. 
Results
Selectivity of URB602 and URB754 for MAGL vs FAAH
In Figure 1a , the effects of URB602 on the hydrolysis of 2-OG by cytosolic and membrane-bound preparations from rat brain are shown and compared with its effects on AEA hydrolysis. URB602 showed no obvious selectivity: the pI 50 values for cytosolic 2-OG hydrolysis and membrane fraction AEA hydrolysis were 4.6070.05 and 4.7670.05, respectively (corresponding to IC 50 values of 25 and 17 mM, respectively). The data shown in the main figure was from experiments conducted in Belgium, but a similar lack of selectivity was seen when corresponding experiments were conducted in Sweden (inset to Figure 1a) . Effects on human recombinant MAGL were also investigated; 2-OG hydrolysis rates of 9570.5, 9570.6, 7378, 4879 and 5473% of vehicle controls were found at URB602 concentrations of 0.3, 3, 10, 30 and 300 mM, respectively (means7s.e.m., n ¼ 3).
URB754 was a weak inhibitor of the hydrolysis of 2-OG by the brain preparations (Figure 1b) . The cytosolic activity was the most affected, with a pI 50 value for URB754 of 4.3170.07, corresponding to an IC 50 value of 48 mM. Membrane-bound 2-OG metabolism (in the presence of 3 mM URB597 to prevent FAAH-catalysed hydrolysis of this substrate) and AEA hydrolysis were only inhibited by about 30% at the highest concentrations of the compound tested. At concentrations of URB754 of 0.3, 3, 10, 30 and 300 mM, the 2-OG hydrolysis rates produced by human recombinant MAGL were 9774, 8177, 9372, 10170.9 and 9174% of vehicle controls, respectively (means7s.e.m., n ¼ 4). Mass spectrometry analyses of the stock solutions of URB754 and URB602 used in these experiments confirmed the levels of purity of the compounds stated by the manufacturers (Waters QToF2 mass spectrometer, source ESI, exact mass ]AEA) and incubation for a further 5 min at 371C. The rates of 2-OG hydrolysis in the presence of 2, 10, 50 and 100 mM URB602 were 10073, 9373, 8373 and 6372% of the corresponding controls, respectively (means7s.e.m., n ¼ 4). The corresponding values for AEA hydrolysis were 9873, 8275, 4576 and 3277%, respectively. URB754 showed little effect, concentrations of 50 and 100 mM producing rates of 10172 and 10073 (2-OG) and 8773 and 8275% (AEA) of control, respectively. In contrast, the selective FAAH inhibitor URB597 almost completely blocked the hydrolysis of AEA by the cells with little or no effect upon the metabolism of 2-OG (data not shown). The effect of 100 mM URB602 was, however, somewhat variable in these cells, as in a subsequent experiment using slightly different conditions, no inhibition of 2-OG hydrolysis was seen at the 100 mM concentration (data not shown).
In C6 cells, URB597 and URB602 had modest effects, and URB754 no effect, upon the metabolism of 2-OG, whereas URB597 potently inhibited the hydrolysis of AEA (Figure 1d) . MAFP, on the other hand greatly inhibited 2-OG hydrolysis (Figure 1d ), consistent with its effects upon recombinant rat MAGL (Dinh et al., 2002) and upon C6 cells when assayed at room temperature using a phenylsepharose extraction method (Brengdahl and Fowler, 2006) . In an additional experiment, a longer (60 min) preincubation time was used in the presence of 1 mM URB597, to minimize any potential contribution by FAAH to the hydrolysis of 2-OG. Under these conditions, the 2-OG metabolism (as % of control) was 7372, 9777, 3875 and 3276 for 30 mM URB602, 10 mM URB754, 1 and 10 mM MAFP, respectively (means7s.e.m., n ¼ 3). In contrast, in the mouse MC3T3-E1 osteoblastic cells, which did not express mRNA for MAGL (Figure 1e ), but which were able to metabolize 2-OG in a time-dependent manner that was only slightly inhibited by URB597 (Figure 1f ), MAFP was a poor inhibitor (Figure 1g ). Although the assay conditions for the MC3T3-E1 and C6 cells were different in terms of incubation times and vehicle concentrations, the data are consistent with the suggestion that the MAFP sensitivity of the 2-OG metabolic activity in the C6 cells correlates with the expression of MAGL. A similar result was seen for the MC3T3-E1 cells when the MAFP was preincubated with the cells for 60, rather than 10 min (data not shown).
Discussion
In the present study, we have investigated the abilities of URB602 and URB754 to inhibit MAGL in view of the diverse potencies of these compounds presented in the literature (Hohmann et al., 2005; Makara et al., 2005; Saario et al., 2006) . The main findings of the study concern the selectivity of URB602 and potency of URB754. We found that URB602 inhibited the hydrolysis of 2-OG by brain cytosolic fractions with an IC 50 value of 25 mM, entirely in line with the study of Hohmann et al. (2005) . A concentration of 30 mM of URB602 also halved the rate of hydrolysis produced by human recombinant MAGL, a result consistent with the data of Makara et al. (2005) for rat recombinant MAGL. However, URB602 had only minor effects, compared to the effects of MAFP, on the hydrolysis of 2-OG by C6 cells that express MAGL. This would suggest that for this cell line, the compound has a limited ability to reach the 2-OG hydrolytic enzymes within the cell. Furthermore, and in contrast to the study of Hohmann et al. (2005) , we did not see any selectivity of the compound for FAAH. The finding that URB602 can increase 2-AG but not AEA levels in cultures of rat brain slices (Hohmann et al., 2005) may indicate that the level of inhibition of hydrolysis required to elevate 2-AG levels is lower than for AEA. An alternative explanation is that the modes of inhibition of MAGL and FAAH by the compound are different, and that under certain conditions selectivity can be achieved. This has not been explored, simply because an at best limited degree of selectivity in vitro is unlikely to be seen in vivo.
The data obtained with URB754, showing little or no effect of this compound upon 2-OG hydrolysis by either cytosolic or membrane fractions, recombinant human MAGL, or intact C6 cells, are entirely in line with the study of Saario et al. (2006) . These authors demonstrated that the compound, at a concentration of 100 mM, did not affect the hydrolysis of 2-AG by brain homogenates, cerebellar homogenates and cerebellar membranes, and at a concentration of 10 mM did not potentiate the ability of 2-AG to stimulate [ 35 S]GTPgS binding to rat brain slices (Saario et al., 2006) . The present data thus underline their suggestion that 'the effects attributed to URB754 in fact represent activity related to another chemical entity' (Saario et al., 2006) . In conclusion, our data indicate that URB602 and URB754 do not behave as selective and/or potent inhibitors of MAGL in vitro, and this places a severe limitation on their usefulness in the elucidation of the role played by this enzyme in the body.
